A publicly traded biopharmaceutical company with a novel technology platform approached Kineticos about supporting their R&D strategy. The organization recently licensed one of their lead development programs to a top 10 pharmaceutical company and was in need of replenishing their pipeline.  Because their platform was broadly applicable across indications, there was a need to conduct an objective indication prioritization exercise.

For the full case study including example deliverables, click here: R&D Strategy

Subscribe to the Kineticos Research Institute to receive weekly emails containing insightful content.